| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| A615 | PY159 Featured |
|
|
| A616 | PY314 Featured |
|
|
| A617 | GBR-900 Featured |
|
|
| A618 | Rinat patent anti-TrkB Featured |
|
|
| A620 | Sacituzumab Featured | Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab is used for the synthesis of antibody-drug conjugates (ADC) drugs. Antibody-drug conjugates with sacituzumab (sacituzumab govitecan) (HY-132254) targeting TROP-2 have been approved for the field of triple-negative breast cancer. |
|
| A621 | Flanvotumab Featured | Flanvotumab (IMC-20D7S) is a human monoclonal antibody targeting to tyrosinase-related protein (TYRP1), specifically expressed in melanocytes and melanoma cells. Flanvotumab acts function via natural killing-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Flanvotumab has potent anti-tumor activity and good tolerance. |
|
| A622 | Anti-TSHR Antibody (K1-70) Featured |
|
|
| A623 | Schering patent anti-TSLP Featured |
|
|
| A624 | Naratuximab Featured | Naratuximab (Anti-TSPAN26/CD37 Reference Antibody (naratuximab)) is a humanized monoclonal antibody that binds CD37 (TSPAN26). Naratuximab can be used to synthesize an ADC compound, Naratuximab emtansine. |
|
| A625 | Otlertuzumab Featured | Otlertuzumab (TRU-016) is a humanized anti-CD37 monoclonal antibody that can be used for cancer research. |
|
| A626 | AGS-67E Featured |
|
|
| A627 | Lilotomab Featured | Lilotomab (HH1) is a murine anti-CD37 monoclonal antibody. Lilotomab reduces clonogenic survival. Lilotomab shows anti-tumor activity. |
|
| A628 | INSERM patent anti-CO-029 Featured |
|
|
| A629 | ELB-031 Featured |
|
|
| A630 | Hanwha patent anti-VCAM-1 Featured |
|
|
| A631 | BioMab patent anti-VEGF Featured |
|
|
| A632 | Domantis patent anti-VEGF Featured |
|
|
| A633 | Anti-VEGFB Antibody (CSL346) Featured |
|
|
| A634 | VGX100 Featured |
|
|
| A635 | Abbott patent anti-Flt1 Featured |
|
|
| A636 | Olinvacimab Featured | Olinvacimab (TTAC-0001) is a fully human anti-VEGFR2 monoclonal antibody. Olinvacimab inhibits VEGF binds to KDR with a Kd value of 0.23 nM. Olinvacimab has antiangiogenic activity. Olinvacimab can be used for the research of recurrent glioblastoma and breast cancer. |
|
| A637 | Vulinacimab Featured | Vulinacimab (HLX-06) is an anti-VEGFR-2 monoclonal antibody (mAb). Vulinacimab can be used in the research of cancers. VEGFR-2, overexpressed in certain tumors, is critical in angiogenesis and the proliferation, survival, migration and differentiation of endothelial cells. |
|
| A638 | Anti-VEGFR2/KDR/CD309 Antibody (AT001) Featured |
|
|
| A639 | Alacizumab Featured |
|
|
| A640 | Imclone 6.64 Featured |
|
|
| A641 | LY3022856 Featured |
|
|
| A642 | Ajinomoto patent anti-vWF Featured |
|
|
| A643 | INSERM patent anti-vWF Featured |
|
|
| A644 | Pimurutamab Featured | Pimurutamab is a humanized IgG1-κ antibody targeting EGFR. Mainly expressed by CHO-K1 cells. |
|
| A645 | Sintilimab Featured | Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer. |
|
